medical coating Applications
-
Natural Bionanomatrix Coating Technologies for Brain Aneurysm Industry
More than 3% of the population has unruptured cerebral aneurysms, approximately 10 million people in the US. About 30,000 rupture per year, with devastating consequences. More than 30% of patients with ruptured aneurysms die, and 4 of 7 who survive have significant disabilities. Detachable microcoils are now used in more than 70% of treated aneurysms. The risk of recurrence, or recanalization, remains surprisingly high at approximately 20-30%. Various modifications are used clinically with limited evidence that ...
By Endomimetics based in Birmingham, ALASKA (USA).
-
Natural Bionanomatrix Coating Technologies for Cardiovascular Disease industry
Stents are the most common cardiovascular implants used in the treatment of cardiovascular diseases. However, there are concerns about in-stent renarrowing (restenosis) with bare metal stents and late stent thrombosis and inflammatory responses with drug-eluting stents. The endothelium is the lining of the blood vessels that is a thin layer of endothelial cells and underlying nanofibrillar basement membrane. It modulates vascular tone by release of factors such as nitric oxide. With stent deployment, there is ...
By Endomimetics based in Birmingham, ALASKA (USA).
-
Natural Bionanomatrix Coating Technologies for BioNanomatrix Industry
. Self-assembling amino acid chains that are free of solvents typically used in device coatings, ...
By Endomimetics based in Birmingham, ALASKA (USA).
-
Medical solutions for orthopedic implant manufacturing sector
include precision machining, finishing, porous coatings, passivation, and ...
By Micron Solutions based in Fitchburg, MASSACHUSETTS (USA).
-
Natural Bionanomatrix Coating Technologies for Dialysis Fistula industry
More than 500,000 U.S. patients have end stage renal disease, and over 80% of them utilize hemodialysis. A significant problem for dialysis patients is the development of a functioning and durable vascular access, preferably an arteriovenous fistula (AVF). After creation, about 60% of AVFs fail to mature successfully for dialysis use. This is due to inadequate vasodilation and smooth muscle cell hyperplasia at the distal venous ...
By Endomimetics based in Birmingham, ALASKA (USA).
-
Multipotent Cell Conditioned Media Technology for Matrix Regeneration
Through the same proprietary manufacturing process that produces CCM and HSC, a novel human extracellular matrix (hECM) is also created and holds potential as a biological matrix to replace or regenerate tissue for therapeutic applications including orthopedics, soft tissue augmentation and wound ...
By Histogen Inc. based in San Diego, CALIFORNIA (USA).
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you